SmartZyme Team

Our Team

Dr. Mark Leavitt

Dr. Mark Leavitt

Position: CTO and VP R&D

Mark Leavitt has over 20 years of expertise in the leadership of discovery and development teams that have driven multiple biotherapeutic programs from early stage through to clinic studies, with particular focus on enzyme replacement therapies for the treatment of metabolic disorders.

Most recently, Dr. Leavitt served as Executive Director and Vice President at Synageva BioPharma and at Alexion Pharmaceuticals following Alexion's acquisition of Synageva, managing the development of several Biotherapeutic entities including Kanuma.

Previous to Alexion, Mark had worked in the areas of anti-viral therapeutics and gene therapy at Pfizer and University of California at San Diego, and obtained his PhD and BS from the University of Arizona.



Interested in working with us?